Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice
The need for more effective influenza vaccines is highlighted by the emergence of novel influenza strains, which can lead to new pandemics. There is a growing population of susceptible subjects at risk for severe complications of influenza, such as the elderly who are only in part protected by curre...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01223/full |
id |
doaj-823265d357f44f59aa1a3b2f3b294ace |
---|---|
record_format |
Article |
spelling |
doaj-823265d357f44f59aa1a3b2f3b294ace2020-11-24T22:29:49ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-09-01810.3389/fimmu.2017.01223289805Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in MiceThomas Ebensen0Jennifer Debarry1Gabriel K. Pedersen2Gabriel K. Pedersen3Gabriel K. Pedersen4Paulina Blazejewska5Sebastian Weissmann6Kai Schulze7Kenneth C. McCullough8Rebecca J. Cox9Rebecca J. Cox10Rebecca J. Cox11Carlos A. Guzmán12Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyThe Influenza Centre, University of Bergen, Bergen, NorwayJebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Research and Development, Haukeland University Hospital, Bergen, NorwayDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyInstitute of Virology and Immunology, Mittelhäusern, SwitzerlandThe Influenza Centre, University of Bergen, Bergen, NorwayJebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Bergen, NorwayDepartment of Research and Development, Haukeland University Hospital, Bergen, NorwayDepartment of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, Braunschweig, GermanyThe need for more effective influenza vaccines is highlighted by the emergence of novel influenza strains, which can lead to new pandemics. There is a growing population of susceptible subjects at risk for severe complications of influenza, such as the elderly who are only in part protected by current licensed seasonal vaccines. One strategy for improving seasonal and pandemic vaccines takes advantage of adjuvants to boost and modulate evoked immune responses. In this study, we examined the capacity of the recently described adjuvant cyclic di-adenosine monophosphate (c-di-AMP) to serve as an adjuvant for improved mucosal influenza vaccines, and induce effective protection against influenza H5N1. In detail, c-di-AMP promoted (i) effective local and systemic humoral immune responses, including protective hemagglutination inhibition titers, (ii) effective cellular responses, including multifunctional T cell activity, (iii) induction of long-lasting immunity, and (iv) protection against viral challenge. Furthermore, we demonstrated the dose-sparing capacity of the adjuvant as well as the ability to evoke cross-clade protective immune responses. Overall, our results suggest that c-di-AMP contributes to the generation of a protective cell-mediated immune response required for efficacious vaccination against influenza, which supports the further development of c-di-AMP as an adjuvant for seasonal and pandemic influenza mucosal vaccines.http://journal.frontiersin.org/article/10.3389/fimmu.2017.01223/fullmucosal adjuvantcyclic di-adenosine monophosphatesublingual administrationc-di-GMPdose-sparing capacity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas Ebensen Jennifer Debarry Gabriel K. Pedersen Gabriel K. Pedersen Gabriel K. Pedersen Paulina Blazejewska Sebastian Weissmann Kai Schulze Kenneth C. McCullough Rebecca J. Cox Rebecca J. Cox Rebecca J. Cox Carlos A. Guzmán |
spellingShingle |
Thomas Ebensen Jennifer Debarry Gabriel K. Pedersen Gabriel K. Pedersen Gabriel K. Pedersen Paulina Blazejewska Sebastian Weissmann Kai Schulze Kenneth C. McCullough Rebecca J. Cox Rebecca J. Cox Rebecca J. Cox Carlos A. Guzmán Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice Frontiers in Immunology mucosal adjuvant cyclic di-adenosine monophosphate sublingual administration c-di-GMP dose-sparing capacity |
author_facet |
Thomas Ebensen Jennifer Debarry Gabriel K. Pedersen Gabriel K. Pedersen Gabriel K. Pedersen Paulina Blazejewska Sebastian Weissmann Kai Schulze Kenneth C. McCullough Rebecca J. Cox Rebecca J. Cox Rebecca J. Cox Carlos A. Guzmán |
author_sort |
Thomas Ebensen |
title |
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice |
title_short |
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice |
title_full |
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice |
title_fullStr |
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice |
title_full_unstemmed |
Mucosal Administration of Cycle-Di-Nucleotide-Adjuvanted Virosomes Efficiently Induces Protection against Influenza H5N1 in Mice |
title_sort |
mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza h5n1 in mice |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2017-09-01 |
description |
The need for more effective influenza vaccines is highlighted by the emergence of novel influenza strains, which can lead to new pandemics. There is a growing population of susceptible subjects at risk for severe complications of influenza, such as the elderly who are only in part protected by current licensed seasonal vaccines. One strategy for improving seasonal and pandemic vaccines takes advantage of adjuvants to boost and modulate evoked immune responses. In this study, we examined the capacity of the recently described adjuvant cyclic di-adenosine monophosphate (c-di-AMP) to serve as an adjuvant for improved mucosal influenza vaccines, and induce effective protection against influenza H5N1. In detail, c-di-AMP promoted (i) effective local and systemic humoral immune responses, including protective hemagglutination inhibition titers, (ii) effective cellular responses, including multifunctional T cell activity, (iii) induction of long-lasting immunity, and (iv) protection against viral challenge. Furthermore, we demonstrated the dose-sparing capacity of the adjuvant as well as the ability to evoke cross-clade protective immune responses. Overall, our results suggest that c-di-AMP contributes to the generation of a protective cell-mediated immune response required for efficacious vaccination against influenza, which supports the further development of c-di-AMP as an adjuvant for seasonal and pandemic influenza mucosal vaccines. |
topic |
mucosal adjuvant cyclic di-adenosine monophosphate sublingual administration c-di-GMP dose-sparing capacity |
url |
http://journal.frontiersin.org/article/10.3389/fimmu.2017.01223/full |
work_keys_str_mv |
AT thomasebensen mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT jenniferdebarry mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT gabrielkpedersen mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT gabrielkpedersen mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT gabrielkpedersen mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT paulinablazejewska mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT sebastianweissmann mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT kaischulze mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT kennethcmccullough mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT rebeccajcox mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT rebeccajcox mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT rebeccajcox mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice AT carlosaguzman mucosaladministrationofcycledinucleotideadjuvantedvirosomesefficientlyinducesprotectionagainstinfluenzah5n1inmice |
_version_ |
1725743028085194752 |